BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1172 related articles for article (PubMed ID: 24094498)

  • 21. Rapid generation of EBV-specific cytotoxic T lymphocytes resistant to calcineurin inhibitors for adoptive immunotherapy.
    Ricciardelli I; Brewin J; Lugthart G; Albon SJ; Pule M; Amrolia PJ
    Am J Transplant; 2013 Dec; 13(12):3244-52. PubMed ID: 24266973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Longitudinal analysis of frequency and reactivity of Epstein-Barr virus-specific T lymphocytes and their association with intermittent viral reactivation.
    Vogl BA; Fagin U; Nerbas L; Schlenke P; Lamprecht P; Jabs WJ
    J Med Virol; 2012 Jan; 84(1):119-31. PubMed ID: 22095540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors.
    Merlo A; Turrini R; Bobisse S; Zamarchi R; Alaggio R; Dolcetti R; Mautner J; Zanovello P; Amadori A; Rosato A
    J Immunol; 2010 May; 184(10):5895-902. PubMed ID: 20385879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.
    Gottschalk S; Edwards OL; Sili U; Huls MH; Goltsova T; Davis AR; Heslop HE; Rooney CM
    Blood; 2003 Mar; 101(5):1905-12. PubMed ID: 12411306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ex vivo priming of naïve T cells into EBV-specific Th1/Tc1 effector cells by mature autologous DC loaded with apoptotic/necrotic LCL.
    Popescu I; Macedo C; Zeevi A; Nellis J; Patterson KR; Logar A; Rowe D; Reyes J; Rao AS; Storkus WJ; Fung JJ; Metes D
    Am J Transplant; 2003 Nov; 3(11):1369-77. PubMed ID: 14525597
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expansion of peripheral CD8+ CD28- T cells in response to Epstein-Barr virus in patients with rheumatoid arthritis.
    Klatt T; Ouyang Q; Flad T; Koetter I; Bühring HJ; Kalbacher H; Pawelec G; Müller CA
    J Rheumatol; 2005 Feb; 32(2):239-51. PubMed ID: 15693083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.
    Burns DM; Crawford DH
    Blood Rev; 2004 Sep; 18(3):193-209. PubMed ID: 15183903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation.
    Icheva V; Kayser S; Wolff D; Tuve S; Kyzirakos C; Bethge W; Greil J; Albert MH; Schwinger W; Nathrath M; Schumm M; Stevanovic S; Handgretinger R; Lang P; Feuchtinger T
    J Clin Oncol; 2013 Jan; 31(1):39-48. PubMed ID: 23169501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.
    Kalra M; Gerdemann U; Luu JD; Ngo MC; Leen AM; Louis CU; Rooney CM; Gottschalk S
    Cytotherapy; 2019 Feb; 21(2):212-223. PubMed ID: 30396848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy.
    Clave E; Agbalika F; Bajzik V; Peffault de Latour R; Trillard M; Rabian C; Scieux C; Devergie A; Socié G; Ribaud P; Adès L; Ferry C; Gluckman E; Charron D; Esperou H; Toubert A; Moins-Teisserenc H
    Transplantation; 2004 Jan; 77(1):76-84. PubMed ID: 14724439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Epstein-Barr Virus Lytic Protein BZLF1 as a Candidate Target Antigen for Vaccine Development.
    Hartlage AS; Liu T; Patton JT; Garman SL; Zhang X; Kurt H; Lozanski G; Lustberg ME; Caligiuri MA; Baiocchi RA
    Cancer Immunol Res; 2015 Jul; 3(7):787-94. PubMed ID: 25735952
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dendritic cells expand Epstein Barr virus specific CD8+ T cell responses more efficiently than EBV transformed B cells.
    Subklewe M; Sebelin K; Block A; Meier A; Roukens A; Paludan C; Fonteneau JF; Steinman RM; Münz C
    Hum Immunol; 2005 Sep; 66(9):938-49. PubMed ID: 16360833
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-uniform
    Burns DM; Ryan GB; Harvey CM; Nagy E; Hughes S; Murray PG; Russell NH; Fox CP; Long HM
    Front Immunol; 2019; 10():2489. PubMed ID: 31736946
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells.
    Tischer S; Priesner C; Heuft HG; Goudeva L; Mende W; Barthold M; Kloeß S; Arseniev L; Aleksandrova K; Maecker-Kolhoff B; Blasczyk R; Koehl U; Eiz-Vesper B
    J Transl Med; 2014 Dec; 12():336. PubMed ID: 25510656
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional CD4(+) and CD8(+) T-cell responses induced by autologous mitomycin C treated Epstein-Barr virus transformed lymphoblastoid cell lines.
    Meij P; Bloemena E; Palmen N; Brink A; Vervoort MB; Meijer CJ; Middeldorp JM
    Cell Immunol; 2001 Feb; 208(1):25-33. PubMed ID: 11277616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A11 Tetramer-assisted characterization of Rta-specific CD8+ T-cell responses in healthy virus carriers.
    Yu HX; Srinivasan N; Ren EE; Chan SH
    Tissue Antigens; 2005 Jun; 65(6):539-43. PubMed ID: 15896201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human CD8+ memory and EBV-specific T cells show low alloreactivity in vitro and in CD34+ stem cell-engrafted NOD/SCID/IL-2Rγc null mice.
    Thomas S; Klobuch S; Sommer M; van Ewijk R; Theobald M; Meyer RG; Herr W
    Exp Hematol; 2014 Jan; 42(1):28-38.e1-2. PubMed ID: 24120693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selection of a diverse TCR repertoire in response to an Epstein-Barr virus-encoded transactivator protein BZLF1 by CD8+ cytotoxic T lymphocytes during primary and persistent infection.
    Silins SL; Cross SM; Elliott SL; Pye SJ; Burrows JM; Moss DJ; Misko IS
    Int Immunol; 1997 Nov; 9(11):1745-55. PubMed ID: 9418135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ex vivo generation of effective Epstein-Barr virus (EBV)-specific CD8+ cytotoxic T lymphocytes from the peripheral blood of immunocompetent Epstein Barr virus-seronegative individuals.
    Metes D; Storkus W; Zeevi A; Patterson K; Logar A; Rowe D; Nalesnik MA; Fung JJ; Rao AS
    Transplantation; 2000 Nov; 70(10):1507-15. PubMed ID: 11118098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simultaneous isolation of CD8(+) and CD4(+) T cells specific for multiple viruses for broad antiviral immune reconstitution after allogeneic stem cell transplantation.
    Zandvliet ML; van Liempt E; Jedema I; Kruithof S; Kester MG; Guchelaar HJ; Falkenburg JH; Meij P
    J Immunother; 2011 Apr; 34(3):307-19. PubMed ID: 21389867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 59.